White Paper

ALS Studies and Lessons Learned From COVID-19

Read more

The disruptions caused by COVID-19 have complicated both the initiation and execution of clinical trials involving therapies targeting amyotrophic lateral sclerosis (ALS). Read our experts’ perspectives on how to flex during this global pandemic.


Chief Medical and Scientific Officer
Vice President, Scientific Solutions, Neuroscience
Executive Director, Project Management, Franchise Area Lead, Pain

Want to learn more about Worldwide Clinical Trials?